GERON CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
GERON CORP (GERN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 27.86 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-03-02
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 10.19M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 1.95M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-06-30 was 4.17M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-03-31 was 11.56M shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 27.86M shares, a 219.77% increase from fiscal 2024.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 8.71M shares, a 77.67% increase from fiscal 2023.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 4.90M shares, a 87.46% increase from fiscal 2022.
- GERON CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 2.62M shares, a 7.28% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 10.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 12.14M shares derived: sum of 2 quarters · filed 2026-03-02 | 16.30M shares derived: sum of 3 quarters · filed 2026-03-02 | 27.86M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 1.95M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 6.11M shares derived: sum of 2 quarters · filed 2025-11-07 | 17.67M shares 10-Q · filed 2025-11-07 | |
| 2025-06-30 | 4.17M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 15.73M shares 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | 11.56M shares 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 8.71M shares 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 4.90M shares 10-K · filed 2024-02-28 | |||
| 2022-12-31 | 2.62M shares 10-K · filed 2023-03-16 | |||
| 2021-12-31 | 2.82M shares 10-K · filed 2022-03-10 | |||
| 2020-12-31 | 460.31K shares 10-K · filed 2021-03-11 | |||
| 2019-12-31 | 1.27M shares 10-K · filed 2020-03-12 | |||
| 2018-12-31 | 1.24M shares 10-K · filed 2019-03-07 | |||
| 2017-12-31 | 188.26K shares 10-K · filed 2018-03-16 | |||
| 2016-12-31 | 585.91K shares 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |